The invention provides bupropion analog compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
Monoamine reuptake inhibitors
Carroll, F., Blough, B., & Abraham, P. (2017). Monoamine reuptake inhibitors. (Patent No. 9,562,001).